transcriptome analysis console (tac) software 4.0.2.15 Search Results


cgp 40215  (ALZA Inc)
90
ALZA Inc cgp 40215
Cgp 40215, supplied by ALZA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/transcriptome+analysis+console+(tac)+software+4%2E0%2E2%2E15/cgp+40215/10__1128_slash_aac__40__6__1448-61-0-16
Average 90 stars, based on 1 article reviews
cgp 40215 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
h3n2 m1  (Sino Biological)
94
Sino Biological h3n2 m1
C57BL/6 mice were vaccinated with H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), <t>NA/M1</t> (Purple), or left unvaccinated (naïve). At 45 days post-vaccination, serum and BAL were collected and serum and BAL IgG ( a , b , d , e ) and BAL IgA ( c , f ) specific for NP (A/Hong Kong/1/68, <t>H3N2)</t> and M1 (A/Aichi/2/68, H3N2) were quantified via ELISA. As a measure of anti-HA specific antibody against IAV A/Hong Kong/1/68 (H3N2), HAI titers in the serum and BAL were quantified ( g , h ). Shown is the 1:40 titer (dotted line) that is thought to be the threshold for a protective titer. LOD (dotted line) = Limit of Detection. Anti-NA antibody in serum and BAL ( i , j ) were quantified via fluorescence-based NAI. LOD (dotted line) = Limit of Detection; Error bars, mean ± s.e.m. Data representative of two independent experiments with n = 4 mice/group. a – j HA/NP vs. naïve: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; NA/NP vs. naïve: # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001; NA/M1 vs. naive: † P < 0.05, †† P < 0.01, ††† P < 0.001, †††† P < 0.0001; HA/NP vs. NA/M1: @ P < 0.05, @@ P < 0.01, @@@ P < 0.001, @@@@ P < 0.0001, NA/NP vs. NA/M1: ǂP < 0.05, ǂǂP < 0.01, ǂǂǂP < 0.001, ǂǂǂǂP < 0.0001, (Two-way ANOVA with Tukey’s multiple comparison test). ( g , h ) **** P < 0.0001 (One-way ANOVA with Tukey’s multiple comparisons test).
H3n2 M1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/transcriptome+analysis+console+(tac)+software+4%2E0%2E2%2E15/Influenza+A+H3N2+(A%2FAichi%2F2%2F1968)+Matrix+protein+1+%2F+M1+Protein/pmc11143372-224-58-60
Average 94 stars, based on 1 article reviews
h3n2 m1 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
trenbolone acetate  (Elanco Inc)
86
Elanco Inc trenbolone acetate
C57BL/6 mice were vaccinated with H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), <t>NA/M1</t> (Purple), or left unvaccinated (naïve). At 45 days post-vaccination, serum and BAL were collected and serum and BAL IgG ( a , b , d , e ) and BAL IgA ( c , f ) specific for NP (A/Hong Kong/1/68, <t>H3N2)</t> and M1 (A/Aichi/2/68, H3N2) were quantified via ELISA. As a measure of anti-HA specific antibody against IAV A/Hong Kong/1/68 (H3N2), HAI titers in the serum and BAL were quantified ( g , h ). Shown is the 1:40 titer (dotted line) that is thought to be the threshold for a protective titer. LOD (dotted line) = Limit of Detection. Anti-NA antibody in serum and BAL ( i , j ) were quantified via fluorescence-based NAI. LOD (dotted line) = Limit of Detection; Error bars, mean ± s.e.m. Data representative of two independent experiments with n = 4 mice/group. a – j HA/NP vs. naïve: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; NA/NP vs. naïve: # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001; NA/M1 vs. naive: † P < 0.05, †† P < 0.01, ††† P < 0.001, †††† P < 0.0001; HA/NP vs. NA/M1: @ P < 0.05, @@ P < 0.01, @@@ P < 0.001, @@@@ P < 0.0001, NA/NP vs. NA/M1: ǂP < 0.05, ǂǂP < 0.01, ǂǂǂP < 0.001, ǂǂǂǂP < 0.0001, (Two-way ANOVA with Tukey’s multiple comparison test). ( g , h ) **** P < 0.0001 (One-way ANOVA with Tukey’s multiple comparisons test).
Trenbolone Acetate, supplied by Elanco Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/transcriptome+analysis+console+(tac)+software+4%2E0%2E2%2E15/acetate+trenbolone/10__1093_slash_tas_slash_txaf128-87-9-25
Average 86 stars, based on 1 article reviews
trenbolone acetate - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
influenza a h3n2 (a/aichi/2/1968) matrix protein 1 / m1 protein  (Sino Biological)
94
Sino Biological influenza a h3n2 (a/aichi/2/1968) matrix protein 1 / m1 protein
C57BL/6 mice were vaccinated with H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), <t>NA/M1</t> (Purple), or left unvaccinated (naïve). At 45 days post-vaccination, serum and BAL were collected and serum and BAL IgG ( a , b , d , e ) and BAL IgA ( c , f ) specific for NP (A/Hong Kong/1/68, <t>H3N2)</t> and M1 (A/Aichi/2/68, H3N2) were quantified via ELISA. As a measure of anti-HA specific antibody against IAV A/Hong Kong/1/68 (H3N2), HAI titers in the serum and BAL were quantified ( g , h ). Shown is the 1:40 titer (dotted line) that is thought to be the threshold for a protective titer. LOD (dotted line) = Limit of Detection. Anti-NA antibody in serum and BAL ( i , j ) were quantified via fluorescence-based NAI. LOD (dotted line) = Limit of Detection; Error bars, mean ± s.e.m. Data representative of two independent experiments with n = 4 mice/group. a – j HA/NP vs. naïve: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; NA/NP vs. naïve: # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001; NA/M1 vs. naive: † P < 0.05, †† P < 0.01, ††† P < 0.001, †††† P < 0.0001; HA/NP vs. NA/M1: @ P < 0.05, @@ P < 0.01, @@@ P < 0.001, @@@@ P < 0.0001, NA/NP vs. NA/M1: ǂP < 0.05, ǂǂP < 0.01, ǂǂǂP < 0.001, ǂǂǂǂP < 0.0001, (Two-way ANOVA with Tukey’s multiple comparison test). ( g , h ) **** P < 0.0001 (One-way ANOVA with Tukey’s multiple comparisons test).
Influenza A H3n2 (A/Aichi/2/1968) Matrix Protein 1 / M1 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/transcriptome+analysis+console+(tac)+software+4%2E0%2E2%2E15/Influenza+A+H3N2+(A%2FAichi%2F2%2F1968)+Matrix+protein+1+%2F+M1+Protein/custom%4040215-v07e%40pmc11133680__DataSheet_2
Average 94 stars, based on 1 article reviews
influenza a h3n2 (a/aichi/2/1968) matrix protein 1 / m1 protein - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


C57BL/6 mice were vaccinated with H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), NA/M1 (Purple), or left unvaccinated (naïve). At 45 days post-vaccination, serum and BAL were collected and serum and BAL IgG ( a , b , d , e ) and BAL IgA ( c , f ) specific for NP (A/Hong Kong/1/68, H3N2) and M1 (A/Aichi/2/68, H3N2) were quantified via ELISA. As a measure of anti-HA specific antibody against IAV A/Hong Kong/1/68 (H3N2), HAI titers in the serum and BAL were quantified ( g , h ). Shown is the 1:40 titer (dotted line) that is thought to be the threshold for a protective titer. LOD (dotted line) = Limit of Detection. Anti-NA antibody in serum and BAL ( i , j ) were quantified via fluorescence-based NAI. LOD (dotted line) = Limit of Detection; Error bars, mean ± s.e.m. Data representative of two independent experiments with n = 4 mice/group. a – j HA/NP vs. naïve: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; NA/NP vs. naïve: # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001; NA/M1 vs. naive: † P < 0.05, †† P < 0.01, ††† P < 0.001, †††† P < 0.0001; HA/NP vs. NA/M1: @ P < 0.05, @@ P < 0.01, @@@ P < 0.001, @@@@ P < 0.0001, NA/NP vs. NA/M1: ǂP < 0.05, ǂǂP < 0.01, ǂǂǂP < 0.001, ǂǂǂǂP < 0.0001, (Two-way ANOVA with Tukey’s multiple comparison test). ( g , h ) **** P < 0.0001 (One-way ANOVA with Tukey’s multiple comparisons test).

Journal: NPJ Vaccines

Article Title: Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection

doi: 10.1038/s41541-024-00883-3

Figure Lengend Snippet: C57BL/6 mice were vaccinated with H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), NA/M1 (Purple), or left unvaccinated (naïve). At 45 days post-vaccination, serum and BAL were collected and serum and BAL IgG ( a , b , d , e ) and BAL IgA ( c , f ) specific for NP (A/Hong Kong/1/68, H3N2) and M1 (A/Aichi/2/68, H3N2) were quantified via ELISA. As a measure of anti-HA specific antibody against IAV A/Hong Kong/1/68 (H3N2), HAI titers in the serum and BAL were quantified ( g , h ). Shown is the 1:40 titer (dotted line) that is thought to be the threshold for a protective titer. LOD (dotted line) = Limit of Detection. Anti-NA antibody in serum and BAL ( i , j ) were quantified via fluorescence-based NAI. LOD (dotted line) = Limit of Detection; Error bars, mean ± s.e.m. Data representative of two independent experiments with n = 4 mice/group. a – j HA/NP vs. naïve: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; NA/NP vs. naïve: # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001; NA/M1 vs. naive: † P < 0.05, †† P < 0.01, ††† P < 0.001, †††† P < 0.0001; HA/NP vs. NA/M1: @ P < 0.05, @@ P < 0.01, @@@ P < 0.001, @@@@ P < 0.0001, NA/NP vs. NA/M1: ǂP < 0.05, ǂǂP < 0.01, ǂǂǂP < 0.001, ǂǂǂǂP < 0.0001, (Two-way ANOVA with Tukey’s multiple comparison test). ( g , h ) **** P < 0.0001 (One-way ANOVA with Tukey’s multiple comparisons test).

Article Snippet: Next, 20:80 CPTEG:CPH nanoparticles containing 2 wt.% CpG (ODN 1668, Invivogen, San Diego, CA) adjuvant as well as 1 wt.% H3N2 HA (Sino Biological, Beijing, China, Catalog # 40116-V08B) and 1 wt.% NP (Sino Biological, Catalog # 40207-V08B), 1 wt.% H3N2 NA (Sino Biological, Catalog # sino) and 1 wt.% NP, or 1 wt.% NA and 1 wt.% H3N2 M1 (Sino Biological, Catalog # 40215-V07E) were synthesized via solid-oil-oil double emulsion .

Techniques: Enzyme-linked Immunosorbent Assay, Fluorescence, Comparison

C57BL/6 mice were vaccinated with H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), NA/M1 (Purple), or left unvaccinated (naïve). At 45 days post vaccination, mice were challenged with a lethal dose of homologous ( a – c ) A/Hong Kong/1/1968 (H3N2) or heterologous ( d – f ) A/Puerto Rico/8/1934 (H1N1). Subsequently, morbidity (i.e., weight loss ( a , d ), lung-airway resistance (Penh) ( b , e )) and mortality ( c , f ) were monitored daily. Error bars, mean ± s.e.m. Data representative of 3 independent experiments with n = 4–5 mice/group. HA/NP vs. naïve: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; NA/NP vs. naïve: # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001; NA/M1 vs. naive: † P < 0.05, †† P < 0.01, ††† P < 0.001, †††† P < 0.0001; HA/NP vs. NA/M1: @ P < 0.05, @@ P < 0.01, @@@ P < 0.001, @@@@ P < 0.0001; NA/NP vs. NA/M1: ǂ P < 0.05; HA/NP vs. NA/NP: ^ P < 0.05, ^^ P < 0.01 ( a , b , d , e ) (Two-way ANOVA with Holm-Sidak multiple comparison test). ( c , f ) (Mantel-Cox Log rank test).

Journal: NPJ Vaccines

Article Title: Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection

doi: 10.1038/s41541-024-00883-3

Figure Lengend Snippet: C57BL/6 mice were vaccinated with H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), NA/M1 (Purple), or left unvaccinated (naïve). At 45 days post vaccination, mice were challenged with a lethal dose of homologous ( a – c ) A/Hong Kong/1/1968 (H3N2) or heterologous ( d – f ) A/Puerto Rico/8/1934 (H1N1). Subsequently, morbidity (i.e., weight loss ( a , d ), lung-airway resistance (Penh) ( b , e )) and mortality ( c , f ) were monitored daily. Error bars, mean ± s.e.m. Data representative of 3 independent experiments with n = 4–5 mice/group. HA/NP vs. naïve: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; NA/NP vs. naïve: # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001; NA/M1 vs. naive: † P < 0.05, †† P < 0.01, ††† P < 0.001, †††† P < 0.0001; HA/NP vs. NA/M1: @ P < 0.05, @@ P < 0.01, @@@ P < 0.001, @@@@ P < 0.0001; NA/NP vs. NA/M1: ǂ P < 0.05; HA/NP vs. NA/NP: ^ P < 0.05, ^^ P < 0.01 ( a , b , d , e ) (Two-way ANOVA with Holm-Sidak multiple comparison test). ( c , f ) (Mantel-Cox Log rank test).

Article Snippet: Next, 20:80 CPTEG:CPH nanoparticles containing 2 wt.% CpG (ODN 1668, Invivogen, San Diego, CA) adjuvant as well as 1 wt.% H3N2 HA (Sino Biological, Beijing, China, Catalog # 40116-V08B) and 1 wt.% NP (Sino Biological, Catalog # 40207-V08B), 1 wt.% H3N2 NA (Sino Biological, Catalog # sino) and 1 wt.% NP, or 1 wt.% NA and 1 wt.% H3N2 M1 (Sino Biological, Catalog # 40215-V07E) were synthesized via solid-oil-oil double emulsion .

Techniques: Comparison